Suguru Fukuhara
YOU?
Author Swipe
View article: Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies
Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies Open
Rogocekib (development name CTX-712) is a first-in-class, orally available, highly potent, and selective small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing process. Preclinical studies demonstrated anti…
View article: <i>Schizophyllum</i> <i>commune</i> infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma
<i>Schizophyllum</i> <i>commune</i> infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma Open
Infectious complications are common following chimeric antigen receptor (CAR) T-cell therapy for B-cell lymphoma due to its prolonged immunosuppressive effects. Schizophyllum commune is an exceedingly rare fungal pathogen that typically af…
View article: 225 | THE FOREST STUDY: A PROSPECTIVE OBSERVATIONAL STUDY ON REAL‐WORLD MANAGEMENT AND OUTCOMES OF FOLLICULAR LYMPHOMA IN JAPAN
225 | THE FOREST STUDY: A PROSPECTIVE OBSERVATIONAL STUDY ON REAL‐WORLD MANAGEMENT AND OUTCOMES OF FOLLICULAR LYMPHOMA IN JAPAN Open
View article: Correlation with Cd79b Expression and Clinicopathological Parameters Including Cell of Origin, Cd79a and Cd19 Expression, and Cd79b Mutation in Diffuse Large B-Cell Lymphoma
Correlation with Cd79b Expression and Clinicopathological Parameters Including Cell of Origin, Cd79a and Cd19 Expression, and Cd79b Mutation in Diffuse Large B-Cell Lymphoma Open
View article: Consideration of the natural history of BCL2-positive follicular lymphoma: based on tumor site, histological grade, and histological transformation rate
Consideration of the natural history of BCL2-positive follicular lymphoma: based on tumor site, histological grade, and histological transformation rate Open
View article: Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305)
Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305) Open
This single‐arm confirmatory study (JCOG1305) aimed to evaluate the utility of interim positron emission tomography (iPET)‐guided therapy for newly diagnosed advanced‐stage classic Hodgkin lymphoma (cHL). Patients aged 16–60 years with cHL…
View article: The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype
The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype Open
View article: Clinical utility of genomic profiling of <scp>AML</scp> using paraffin‐embedded bone marrow clots: <scp>HM‐SCREEN‐Japan</scp> 01
Clinical utility of genomic profiling of <span>AML</span> using paraffin‐embedded bone marrow clots: <span>HM‐SCREEN‐Japan</span> 01 Open
Next‐generation sequencing of AML has identified specific genetic mutations in AML patients. Hematologic Malignancies (HM)‐SCREEN‐Japan 01 is a multicenter study to detect actionable mutations using paraffin‐embedded bone marrow (BM) clot …
View article: Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases
Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases Open
We report two cases of diffuse large B-cell lymphoma (DLBCL) with composite germinal center B-cell (GCB) and non-GCB types. Case 1 was a 72-year-old woman with inguinal lymph node swelling. Two morphologically different lesions were concur…
View article: Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies Open
Tirabrutinib is a Bruton’s tyrosine kinase inhibitor for treating B-cell malignancies. We report the final results of a Phase I study of tirabrutinib in 17 Japanese patients with B-cell malignancies. Patients were administered tirabrutinib…
View article: Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (<scp>JCOG1105</scp>)
Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (<span>JCOG1105</span>) Open
We conducted a randomized phase II study to determine a more promising modified MPB regimen for TI-NDMM (JCOG1105, jRCTs031180097). The primary analysis in JCOG1105 revealed that Arm A (known as PETHEMA/GEM05 MPB) showed a higher CR rate a…
View article: Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies Open
Identification of genetic alterations through next‐generation sequencing (NGS) can guide treatment decision‐making by providing information on diagnosis, therapy selection, and prognostic stratification in patients with hematological malig…
View article: The outcome of watchful waiting in patients with previously treated follicular lymphoma
The outcome of watchful waiting in patients with previously treated follicular lymphoma Open
Watchful waiting (WW) is one of the standard approaches for newly diagnosed follicular lymphoma (FL) patients with low‐tumor burden. However, the impact of WW in FL patients at the first progression, remains unclear. We reviewed 206 FL pat…
View article: The role of surveillance computed tomography in patients with follicular lymphoma
The role of surveillance computed tomography in patients with follicular lymphoma Open
Introduction: Surveillance computed tomography (CT) is performed during the follow-up of patients with lymphoma who have completed initial therapy. However, studies on the clinical benefit of surveillance CT for patients with incurable sub…
View article: Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy Open
Background Approximately 15% of patients with diffuse large B‐cell lymphoma (DLBCL) experience refractory or early relapsed disease after initial rituximab‐containing chemoimmunotherapy is regarded as a primary refractory disease. Although…
View article: CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib Open
Mantle cell lymphoma (MCL) is a rare subtype of non‐Hodgkin's lymphoma, which is characterized by overexpression of cyclin D1. Although novel drugs, such as ibrutinib, show promising clinical outcomes, relapsed MCL often acquires drug resi…
View article: Use of Core-Needle Biopsy for the Diagnosis of Malignant Lymphomas in Clinical Practice
Use of Core-Needle Biopsy for the Diagnosis of Malignant Lymphomas in Clinical Practice Open
Introduction: Excisional biopsy (EB) is considered the gold standard for lymphoma diagnosis. Although recent advances in interventional radiology enable sampling with core-needle biopsy (CNB), only few studies evaluated the u…
View article: The role of local radiotherapy following rituximab‐containing chemotherapy in patients with transformed indolent B‐cell lymphoma
The role of local radiotherapy following rituximab‐containing chemotherapy in patients with transformed indolent B‐cell lymphoma Open
Objectives This study aimed to evaluate the outcomes of local radiotherapy (LRT) in patients with histologic transformation (HT) following rituximab‐containing chemotherapy. Methods We retrospectively analysed 92 patients with biopsy‐confi…
View article: A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia Open
Objective Fludarabine, cyclophosphamide and rituximab (FCR) is the standard regimen for fit patients with untreated CD20-positive chronic lymphocytic leukemia (CLL). However, this combination is unavailable in Japan because rituximab is no…
View article: Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma
Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma Open
Although histologic analysis is the gold standard for diagnosing follicular lymphoma (FL) transformation, many patients are diagnosed with transformation by clinical factors as biopsy specimens often cannot be obtained. Despite the frequen…
View article: Acute megakaryoblastic leukaemia with t(1;22)(p13·3;q13·1)/<i>RBM15‐MKL1</i> in an adult patient following a non‐mediastinal germ cell tumour
Acute megakaryoblastic leukaemia with t(1;22)(p13·3;q13·1)/<i>RBM15‐MKL1</i> in an adult patient following a non‐mediastinal germ cell tumour Open
Acute megakaryoblastic leukaemia (AMKL) is a rare subtype of acute myeloid leukaemia (AML) that accounts for 1% of adult AML cases. AMKL is a more common subtype of childhood or infant AML, that occurs especially in children with Down synd…
View article: Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors
Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors Open
View article: COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma
COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma Open
Although some patients with COVID-19 develop only mild symptoms, fatal complications have been observed among those with comorbidities. As patients with cancer are immunocompromised, they are thought to have a high risk of severe illness a…
View article: Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin Open
This is the first case report of alectinib as a bridge to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapies and BV. This report offers a ray of hope for a condition with poor prognosis.
View article: Phase I study of tirabrutinib (<scp>ONO</scp>‐4059/<scp>GS</scp>‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
Phase I study of tirabrutinib (<span>ONO</span>‐4059/<span>GS</span>‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan Open
We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second‐generation, enhanced‐selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B‐c…
View article: Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab Open
Paraneoplastic pemphigus (PNP) is a severe autoimmune blistering disease associated with an underlying malignancy, and its prognosis is poor. We herein report the first patient with B-cell chronic lymphocytic leukemia/small lymphocytic lym…
View article: Cross-Sectional Patient Survey on the Need for a Long-Term Follow-up Program after Autologous Hematopoietic Cell Transplantation
Cross-Sectional Patient Survey on the Need for a Long-Term Follow-up Program after Autologous Hematopoietic Cell Transplantation Open
自家造血幹細胞移植併用大量化学療法 (自家移植) 後の合併症，および移植後長期フォローアップ (long-term follow up, LTFU) 外来に対する患者ニーズを明らかにするため，郵送法による自記式質問紙を用いた単施設の横断的調査を行った。1993年から2014年に造血器腫瘍に対して当院で自家移植を行った231人のうち，無増悪生存で当院への外来通院継続中の71人を対象とし，43人 (61%) から回答を得た。28人 (回答者の65%) が53件の自家移植後合併症…
View article: Fertility and social reintegration after modified <scp>CODOX</scp>‐<scp>M/IVAC</scp> with or without rituximab: A questionnaire survey of non‐<scp>H</scp>odgkin lymphoma
Fertility and social reintegration after modified <span>CODOX</span>‐<span>M/IVAC</span> with or without rituximab: A questionnaire survey of non‐<span>H</span>odgkin lymphoma Open
Introduction: Although malignant lymphoma is one of the most common malignancies among adolescents and young adults (AYAs), there has been limited information regarding their long-term outcome after completion of anti-lymphoma therapies, e…
View article: ONO‐4059 (GS‐4059), A NEXT GENERATION BTK INHIBITOR, MONOTHERAPY IN PATIENTS WITH B‐CELL MALIGNANCIES IN THE JAPANESE PHASE 1, DOSE‐ESCALATION STUDY
ONO‐4059 (GS‐4059), A NEXT GENERATION BTK INHIBITOR, MONOTHERAPY IN PATIENTS WITH B‐CELL MALIGNANCIES IN THE JAPANESE PHASE 1, DOSE‐ESCALATION STUDY Open
Introduction: Bruton's tyrosine kinase (BTK) plays an important role in B-cell signaling, cell proliferation and survival. The highly selective BTK inhibitor, ONO-4059 (GS-4059) showed manageable safety and tolerability as a single agent i…
View article: ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA
ASSESSMENT INDEX OF CLINICAL TRANSFORMATION FROM FOLLICULAR LYMPHOMA (FL) TO DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA Open
Introduction: Histological transformation (HT) remains a critical event because the prognosis of FL with HT is poorer than that of FL without HT even in the rituximab era. The diagnosis of HT by biopsy is the gold standard diagnostic appro…